Gain Therapeutics, Inc. (GANX) Form 10-Q — Aug 11, 2026
Gain Therapeutics reported substantial doubt about its ability to continue as a going concern in its Q2 2026 10-Q, holding $13.1 million in cash against a $9.4 million operating cash burn for the first half of 2026. The company states it must raise additional capital to fund operations beyond the second quarter of 2027 and plans to use equity or convertible debt financings while cutting costs. Q2 net loss narrowed to $4.7 million, or $0.11 per share, from $5.8 million a year earlier, as R&D expense fell to $2.1 million on lower rexaceract program costs; the accumulated deficit reached $111.6 million and cash declined from $20.8 million at year-end 2025.
Key figures
- Total Debt
- $0.34 million
- Total Assets
- 15421939
- Cash Position
- 13084144
- Shares Outstanding
- 43643619
- Cash Runway
- funds operations into Q2 2027
- Ga Expense Q2
- 2543448
- Rd Expense Q2
- 2138204
- Cash Dec312025
- 20837628
- Accumulated Deficit
- $111.6 million
- Atm Program Capacity
- $50.0 million
- Rd Expense Six Months
- 4901544
- Rd Expense Q2 Prior Year
- 2758973
- Subsequent Atm Avg Price
- $1.85
- Atm Shares Sold Six Months
- 963702
- Litigation Damages Sought
- in excess of $3.1 million
- Shares Outstanding June30
- 43340501
- Subsequent Atm Shares Sold
- 300229
- Subsequent Atm Gross Proceeds
- $0.56 million
- Atm Gross Proceeds Since Inception
- $23.9 million
- Total Equity Raised Since Inception
- $122 million
- Research Commitments Within One Year
- $2.4 million
Price after filing
Close on the filing date to close N calendar days later (from $1.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.